Why the IDT (ASX:IDT) share price is rocketing 25% on Wednesday

The company claims it can make 100 million doses of mRNA vaccine within 18 months.
The post Why the IDT (ASX:IDT) share price is rocketing 25% on Wednesday appeared first on The Motley Fool Australia. –

The IDT Australia Limited (ASX: IDT) share price is shooting 25% higher after The Sydney Morning Herald (SMH) reported the company is seeking to work with the federal government to produce mRNA vaccines in Australia.

At the time of writing, shares in the pharmaceutical company are trading for 46.5 cents each – up 25.68%.

Let’s take a closer look at what’s getting investors so excited.

IDT says it can manufacture mRNA vaccines in Australia

The COVID-19 pandemic has heralded the first wide-scale use of mRNA vaccines. The leading products in this space are the inoculations jointly produced by Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), as well as the Moderna Inc (NASDAQ: MRNA) jab.

In an effort to secure domestic supply through the production of the vector for single-strand RNA of viruses, the federal government has been in talks with the companies in a bid to secure a licence for their COVID vaccines to be made in Australia. As well as IDT, CSL Limited (ASX: CSL) is interested in the production of mRNA vaccines on our shores.

IDT says what differentiates its offer from CSL’s is it will use existing manufacturing capabilities located near Melbourne’s Monash University to make the product. CSL is proposing 2 new facilities for the endeavour, according to the SMH.

The prospect of IDT being awarded a lucrative government contract may be exciting investors, judging by the IDT share price rise.

“This is an established site with an established equipment train in it, which we will expand, and I think that gives us a material time advantage,” IDT Chief Executive David Sparling is quoted in the SMH as saying.

“We’ve formed an alliance with numerous research bodies around the country, including Monash University, and that builds an ecosystem for mRNA.”

Dr Sparling further went on to tell the paper his company could produce “100 million doses within 18 months.”

IDT says it wants to build an mRNA research facility near its production site if it secures the licence to make the product. Dr Sparling did not reveal any financial details to the SMH.

Motley Fool Australia reached out to IDT for comment and/or verification but, despite assurances, none had arrived before publication.

IDT share price snapshot

Over the past 12 months, the IDT share price has increased 141%. The company’s shares faced a similar boom when IDT revealed it was in discussions with the Victorian government over a proposed mRNA vaccine plant.

IDT Australia has a market capitalisation of around $104 million.

The post Why the IDT (ASX:IDT) share price is rocketing 25% on Wednesday appeared first on The Motley Fool Australia.

Should you invest $1,000 in IDT Australia right now?

Before you consider IDT Australia, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and IDT Australia wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

ASX investors were buying Robinhood, Square shares last week

Why Pfizer shot 4% higher on Tuesday

Better biotech stock: Moderna vs. BioNTech

Why the Pfizer share price shot higher on Wednesday

TGA approves Pfizer vaccine for kids aged 12-15 years old

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!